FDA deems AML drug breakthrough therapy

05:12 EDT 31 Jul 2017 | SmartBrief

Venclexta, developed by AbbVie and Roche Holding, gained breakthrough therapy designation from the FDA for use with low-dose  -More

Original Article: FDA deems AML drug breakthrough therapy


More From BioPortfolio on "FDA deems AML drug breakthrough therapy"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...